Asset Seizure

Showing 1526 articles
Business

OR Royalties: A Buying Opportunity After Pullback, or a Sign of Overheating?

Shares of OR Royalties (TSX:OR) have retreated nearly 15% over the past week, prompting investors to reassess the valuation of the precious metals royalty company following its multi-year bull run. With the stock still up significantly year-over-year, we examine whether the dip presents a value entry or reflects justified concerns over its premium pricing.

Business

Gilead Sciences Bets on Precision Oncology to Power Next Growth Phase

Gilead Sciences, the biopharma giant known for its HIV treatments, is strategically pivoting to become a major player in cancer therapy. Through targeted licensing and a focus on precision oncology, the company aims to build a multi-billion dollar revenue stream by the end of the decade, reducing its reliance on mature franchises.

Business

The Trade Desk's 80% Plunge: Bargain Hunt or Value Trap for Investors?

Once a high-flying adtech darling, The Trade Desk has seen its stock crater nearly 80% from its peak amid a fierce battle with Amazon's ad juggernaut. With shares now trading at a significant discount to the market, analysts are divided on whether this marks a historic buying opportunity or signals deeper structural challenges.

Business

Simon Property Group Caps Strong Year with Strategic Acquisitions and Record Returns, Outlines Aggressive 2026 Growth Plan

Simon Property Group reported robust fourth-quarter and full-year 2025 results, highlighted by record funds from operations, $2 billion in strategic acquisitions, and a significant return of capital to shareholders. The retail REIT giant provided optimistic 2026 guidance, banking on a strong development pipeline and resilient tenant demand despite acknowledging tariff-related headwinds.